{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:56:05Z","timestamp":1781304965123,"version":"3.54.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI158666"],"award-info":[{"award-number":["R01AI158666"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI078881"],"award-info":[{"award-number":["R01AI078881"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["Z01 BK 04010-18LHV"],"award-info":[{"award-number":["Z01 BK 04010-18LHV"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People who inject drugs (PWIDs) are at high risk for acquiring and transmitting hepatitis C virus (HCV). Direct-acting antiviral (DAA) therapy leads to high cure rates. However, lack of protective immunity after cure and high re-infection rates in PWID necessitates access to multiple DAA treatments per PWID to reach the World Health Organization HCV elimination goal of 90% incidence reduction. A major public health challenge is determining the proportion of PWID to treat to reach the goal and the continued treatment levels required to maintain decreased incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We used an agent-based model to study varying levels of DAA treatment among HCV-infected PWID from Chicago, IL, and the effects of reducing DAA treatment after elimination is reached. The model uses individual temporal viral load profiles to determine transmission probabilities relative to the HCV RNA titers of receptive syringe-sharing PWID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Modeling predicts that insufficient DAA treatment can result in a continuous increase of HCV incidence over a 25-year period, with no significant decrease. Elimination can be achieved within 10 years with sufficient treatment levels. However, when DAA treatment is stopped, rates of new chronic HCV infections rapidly increase, returning to preelimination levels within 5 years. Annual treatment of \u22650.5% would maintain the elimination goal, but identifying and treating small numbers of infected people annually in PWID populations would be resource intensive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The challenge to achieve and maintain the elimination goal underscores the importance of augmenting DAA treatment with intervention strategies such as syringe service programs and vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag297","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:43:36Z","timestamp":1780656216000},"source":"Crossref","is-referenced-by-count":0,"title":["Modeling Highlights the Challenge of Achieving and Maintaining Hepatitis C Virus Micro-Elimination Among People Who Inject Drugs"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-4255","authenticated-orcid":false,"given":"Eric","family":"Tatara","sequence":"first","affiliation":[{"name":"Consortium for Advanced Science and Engineering, University of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Decision and Infrastructure Sciences, Argonne National Laboratory , Argonne, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Shekhtman","sequence":"additional","affiliation":[{"name":"Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]},{"name":"Department of Information Science and Applied AI, Bar-Ilan University , Ramat Gan ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-4156","authenticated-orcid":false,"given":"Nicholson","family":"Collier","sequence":"additional","affiliation":[{"name":"Consortium for Advanced Science and Engineering, University of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Decision and Infrastructure Sciences, Argonne National Laboratory , Argonne, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J","family":"Cotler","sequence":"additional","affiliation":[{"name":"Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-5240","authenticated-orcid":false,"given":"Mary Ellen","family":"Mackesy-Amiti","sequence":"additional","affiliation":[{"name":"Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-8894","authenticated-orcid":false,"given":"Basmattee","family":"Boodram","sequence":"additional","affiliation":[{"name":"Division of Community Health Sciences, School of Public Health, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-1817","authenticated-orcid":false,"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[{"name":"Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-359X","authenticated-orcid":false,"given":"Marian","family":"Major","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-6735","authenticated-orcid":false,"given":"Jonathan","family":"Ozik","sequence":"additional","affiliation":[{"name":"Consortium for Advanced Science and Engineering, University of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Decision and Infrastructure Sciences, Argonne National Laboratory , Argonne, Illinois ,","place":["USA"]},{"name":"Department of Public Health Sciences, The University of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Northwestern-Argonne Institute for Science and Engineering , Evanston, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026061218090252400_ofag297-B1","author":"WHO"},{"key":"2026061218090252400_ofag297-B2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/HEP.0000000000000927","article-title":"Estimating hepatitis C prevalence in the United States, 2017\u20132020","volume":"81","author":"Hall","year":"2025","journal-title":"Hepatology"},{"key":"2026061218090252400_ofag297-B3","author":"U.S. Centers for Disease Control and Prevention"},{"key":"2026061218090252400_ofag297-B4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.drugpo.2019.10.004","article-title":"Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs","volume":"74","author":"Lambdin","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2026061218090252400_ofag297-B5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"2026061218090252400_ofag297-B6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global elimination of chronic hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061218090252400_ofag297-B7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-med-050223-111239","article-title":"Global elimination of hepatitis C virus","volume":"76","author":"Fleurence","year":"2025","journal-title":"Annu Rev Med"},{"key":"2026061218090252400_ofag297-B8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-003767","article-title":"Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination","volume":"5","author":"Boeke","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2026061218090252400_ofag297-B9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/pathogens13080681","article-title":"Hepatitis C elimination in Egypt: story of success","volume":"13","author":"Gomaa","year":"2024","journal-title":"Pathogens"},{"key":"2026061218090252400_ofag297-B10","volume-title":"A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017"},{"key":"2026061218090252400_ofag297-B11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1377\/hlthaff.2018.05232","article-title":"A transitioning epidemic: how the opioid crisis is driving the rise in hepatitis C","volume":"38","author":"Powell","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"2026061218090252400_ofag297-B12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/v12080799","article-title":"Reversal of T cell exhaustion in chronic HCV infection","volume":"12","author":"Osuch","year":"2020","journal-title":"Viruses"},{"key":"2026061218090252400_ofag297-B13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.571166","article-title":"Reversal of immunity after clearance of chronic HCV infection-all reset?","volume":"11","author":"Wedemeyer","year":"2020","journal-title":"Front Immunol"},{"key":"2026061218090252400_ofag297-B14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103422","article-title":"Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort","volume":"96","author":"Carson","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2026061218090252400_ofag297-B15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"key":"2026061218090252400_ofag297-B16","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciac272","article-title":"High rate of hepatitis C virus reinfection among recently injecting drug users: results from the TraP hep C program-A prospective nationwide, population-based study","volume":"75","author":"Johannesson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026061218090252400_ofag297-B17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061218090252400_ofag297-B18","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1473-3099(16)30325-5","article-title":"Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease study 2013","volume":"16","author":"Degenhardt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026061218090252400_ofag297-B19","author":"CDC","year":"2021"},{"key":"2026061218090252400_ofag297-B20","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/OLQ.0000000000000842","article-title":"Syphilis elimination: lessons learned again","volume":"45","author":"Valentine","year":"2018","journal-title":"Sex Transm Dis"},{"key":"2026061218090252400_ofag297-B21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/v15071413","article-title":"Hepatitis C elimination: opportunities and challenges in 2023","volume":"15","author":"Taha","year":"2023","journal-title":"Viruses"},{"key":"2026061218090252400_ofag297-B22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4496","article-title":"Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users","volume":"10","author":"Major","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026061218090252400_ofag297-B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2021.108756","article-title":"Machine learning for mathematical models of HCV kinetics during antiviral therapy","volume":"343","author":"Churkin","year":"2022","journal-title":"Math Biosci"},{"key":"2026061218090252400_ofag297-B24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/QAI.0b013e318050d260","article-title":"Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study","volume":"45","author":"Huo","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061218090252400_ofag297-B25","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1097\/QAI.0000000000001406","article-title":"Injection-related risk behavior and engagement in outreach, intervention and prevention services across 20 US cities","volume":"75","author":"Mackesy-Amiti","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061218090252400_ofag297-B26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugalcdep.2015.06.042","article-title":"The role of social networks and geography on risky injection behaviors of young persons who inject drugs","volume":"154","author":"Boodram","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2026061218090252400_ofag297-B27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248850","article-title":"People who inject drugs in metropolitan Chicago: a meta-analysis of data from 1997\u20132017 to inform interventions and computational modeling toward hepatitis C microelimination","volume":"17","author":"Boodram","year":"2022","journal-title":"PLoS One"},{"key":"2026061218090252400_ofag297-B28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/j.gastro.2005.01.049","article-title":"Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production","volume":"128","author":"Dahari","year":"2005","journal-title":"Gastroenterology"},{"key":"2026061218090252400_ofag297-B29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.02.022","article-title":"HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir","volume":"64","author":"Dahari","year":"2016","journal-title":"J Hepatol"},{"key":"2026061218090252400_ofag297-B30","doi-asserted-by":"crossref","first-page":"17820","DOI":"10.1038\/s41598-020-74568-x","article-title":"Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a pilot study","volume":"10","author":"Etzion","year":"2020","journal-title":"Sci Rep"},{"key":"2026061218090252400_ofag297-B31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026061218090252400_ofag297-B32","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.14170","article-title":"Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study","volume":"39","author":"Persico","year":"2019","journal-title":"Liver Int"},{"key":"2026061218090252400_ofag297-B33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2019.02.018","article-title":"Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy","volume":"71","author":"Macias","year":"2019","journal-title":"J Hepatol"},{"key":"2026061218090252400_ofag297-B34","doi-asserted-by":"crossref","DOI":"10.1109\/WSC.2016.7822090","article-title":"From desktop to large-scale model exploration with swift\/T","author":"Ozik","year":"2016"},{"key":"2026061218090252400_ofag297-B35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264983","article-title":"Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago","volume":"17","author":"Tatara","year":"2022","journal-title":"PLoS One"},{"key":"2026061218090252400_ofag297-B36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137993","article-title":"Agent-based model forecasts aging of the population of people who inject drugs in metropolitan Chicago and changing prevalence of hepatitis C infections","volume":"10","author":"Gutfraind","year":"2015","journal-title":"PLoS One"},{"key":"2026061218090252400_ofag297-B37","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1128\/JVI.76.13.6586-6595.2002","article-title":"Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge","volume":"76","author":"Major","year":"2002","journal-title":"J Virol"},{"key":"2026061218090252400_ofag297-B38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000076643","article-title":"Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission","volume":"47","author":"Katayama","year":"2004","journal-title":"Intervirology"},{"key":"2026061218090252400_ofag297-B39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0042-6822(03)00461-6","article-title":"Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees","volume":"314","author":"Shata","year":"2003","journal-title":"Virology"},{"key":"2026061218090252400_ofag297-B40","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1182\/blood-2011-12-393637","article-title":"Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomes","volume":"119","author":"Busch","year":"2012","journal-title":"Blood"},{"key":"2026061218090252400_ofag297-B41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/pathogens13010045","article-title":"A composite score for predicting vertical transmission of hepatitis C: a multicenter study","volume":"13","author":"Wasuwanich","year":"2024","journal-title":"Pathogens"},{"key":"2026061218090252400_ofag297-B42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/AOG.0000000000005872","article-title":"Prediction of hepatitis C virus perinatal transmission in pregnant individuals with hepatitis C virus infection","volume":"145","author":"Sandoval","year":"2025","journal-title":"Obstet Gynecol"},{"key":"2026061218090252400_ofag297-B43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202109","article-title":"HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era","volume":"13","author":"Gountas","year":"2018","journal-title":"PLoS One"},{"key":"2026061218090252400_ofag297-B44","article-title":"Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?","volume":"96","author":"Delaunay","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2026061218090252400_ofag297-B45","doi-asserted-by":"crossref","first-page":"e0210173","DOI":"10.1371\/journal.pone.0210173","article-title":"Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography","volume":"14","author":"Shteyer","year":"2019","journal-title":"PLOS ONE"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag297\/68479838\/ofag297.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag297\/68479838\/ofag297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag297\/68479838\/ofag297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:09:15Z","timestamp":1781302155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag297\/8702891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag297","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag297"}}